Controversies in Cardiac Surgery

Size: px
Start display at page:

Download "Controversies in Cardiac Surgery"

Transcription

1 Controversies in Cardiac Surgery 3 years after SYNTAX : Percutaneous Coronary Intervention for Multivessel / Left main stem Coronary artery disease Pro ESC Congress 2010, 28 August 1 September Stockholm Marie-Claude MORICE, MD, FESC, FACC Massy, France

2 Introduction The optimal revascularization strategy for multivessel disease and Left main stenosis is controversial for long time. Technical innovations are faster than performance of clinical trials, making results of randomized studies outdated at the time of appearance.

3 SYNTAX trial: The Reality SYNTAX represents only a minority of daily patients in a catheterization laboratory. It excluded patients with one or Two-vessel disease and those with an acute coronary syndrome in whom PCI has demonstrated to improve prognosis. SYNTAX represents only a minority of daily patients in a catheterization laboratory

4 Revascularization of CAD in perspective Acute Coronary Syndromes In the acute phase of NSTEMI-ACS/STEMI, PCI is preferred revascularisation procedure, CABG is performed in only 2% of patients. About 50% of PCI are performed for ACS Alexiou K et al. Clin Res Cardiol.2008; 97(9): Van de Werf F et al. Eur Heart J.2008; 29:

5 knowledge available prior to SYNTAX trial: Stable CAD Revascularization - in the failure of medical therapy or moderate to large amounts of inducible ischemia Single- or two-vessel disease PCI is the preferred revascularization method Three-vessel disease or left main stenosis, PCI and CABG have similar overall mortality. PCI has more reinterventions, Conflicting data on the impact of diabetes mellitus

6 Stable coronary artery disease Three-vessel disease and left main disease In patients with reduced left ventricular function, CABG is considered being the gold standard based on clinical trials conducted in the 1970s and 1980s. Questionable if we compare historical data with modern, optimal medical therapy which has improved over the last decades. Takaro T et al. Circulation 54(suppl III)1976:III-107 III-117 Yusuf S et al. Lancet.1994; 344:

7 23 randomized trials with 9,963 patients. The difference in survival after PCI or CABG was less than 1% over 10 years of follow-up. Repeated revascularization was more common after PCI than after CABG (risk difference, 24% at 1 year and 33% at 5 years). Bravata DM et al. Ann Intern Med.2007; 147:

8 Stroke risk Procedure-related strokes were more common after CABG than after PCI Bravata DM et al. Ann Intern Med.2007; 147:

9 Five-year survival with balloon angioplasty or stents versus coronary artery bypass grafting (CABG) in patients with multivessel disease (MVD). Bravata DM et al. Ann Intern Med.2007; 147:

10 Five-year survival in patients with diabetes. Survival did not differ between PCI and CABG for patients with diabetes in the six trials. Bravata DM et al. Ann Intern Med.2007; 147:

11 10 randomized trials with 7,812 patients. No overall difference in mortality between CABG and PCI (Mortality rates - 15 vs. 16% over a median follow-up time of 5.9 years). Hlatky MA et al. Lancet.2009; 373:

12 Outcomes of treatment with coronary artery bypass graft or percutaneous coronary intervention Overall unadjusted mortality (A) and composite endpoint of death or myocardial infarction (B) after randomization to CABG or PCI. Hlatky MA et al. Lancet.2009; 373:1190

13 Left Main Stenosis Until now, no large randomized trial compared the outcomes of patients with isolated left main stenosis. However, many recent trials suggested the safety of PCI in this indication. Kereiakes D et al.circulation.2006; 113(21): Moses JW et al.j Am Coll Cardiol.2009; 54(16):

14 SYNTAX Trial Design 62 EU Sites + 23 US Sites Heart Team (surgeon & interventionalist) Amenable for both treatment options Stratification: LM and Diabetes Amenable for only one treatment approach Randomized Arms N=1800 Two Registry Arms N=1275 CABG n=897 vs TAXUS * n=903 CABG n=1077 PCI n=198 3VD 66.3% LM 33.7% 3VD 65.4% LM 34.6% 5yr f/u n=649 no f/u n=428 * TAXUS Express Serruys PW, Morice MC et al. N Engl J Med :961

15 Major strengths of the SYNTAX trial Contrast to previous trials where only 5% of eligible patients were randomized, All comer trial with few exclusion criteria (in fact, 71% of screened patients were included into the study). decision to randomise a patient into the study was made by a heart team, - an invasive cardiologist and a cardiac surgeon. Serruys PW, Morice MC et al. N Engl J Med :

16 Hypothesis of SYNTAX PCI is not inferior to CABG with respect to the combined endpoint (MACCE), throughout the 12- months period after randomization. However, the primary outcome of SYNTAX rejected this hypothesis With a significantly higher combined event rate of 17.8% in the PCI group versus 12.4% in the CABG group PCI was statistically not non inferior Serruys PW, Morice MC et al. N Engl J Med :

17 Looking results in detail Endpoint(s) Are the components of the combined endpoint are of same relevance or is there a hierarchy of importance? Subgroups Do the results differ between various subgroups, especially those being predefined? Technical considerations Do revascularization techniques used for either PCI or CABG in SYNTAX differ from what is now thought to be optimal?

18 Endpoint(s) The combined endpoint was basically driven by a reduction of repeated revascularization procedures with CABG (5.9 vs. 13.5%) Death and myocardial infarction at most demonstrated a nonsignificant trend. Stroke rates significantly higher with CABG compared to PCI (2.2 vs. 0.6%). Combining all hard events with long-lasting consequences (death, myocardial infarction, stroke), event rate is nearly identical in the PCI group (7.6%) and in the CABG group (7.7%).

19 Absolute difference in 12 months clinical event rate in the SYNTAX trial: All Patients PCI better CABG better PCI better CABG better Reichenspurner,Clin Res Cardiol july 2010

20 Repeat Revascularization vs CABG Repeat Revascularization CABG In 80% of patients randomized to PCI, repeated revascularization was a new PCI. Neuro-cognitive decline - adverse events, which not included in the combined study end point. repeated PCI procedures - inconvenient due to another short hospital stay, More invasive than PCI with more patient discomfort due to open chest surgery but are not necessarily serious or with further sequelae SYNTAX trial, post-procedural hospital stay was significantly prolonged in the CABG group (9.5 ± 8.0 vs. 3.4 ± 4.5 days) Feldman TE. Presented at TCT 2009

21 Criticism of the SYNTAX trial Short duration of follow-up (only 1 year) Late stent thrombosis after DES implantation, leading to myocardial infarction or death and long term beneficial effects of arterial grafts may diverge hard events, in favor for CABG in the long term follow-up ( 0.5,0.6%/year) 2-years follow-up of SYNTAX, no significant difference in hard clinical events (death, MI, stroke) at 2 years (10.8% PCI, 9.6% CABG). Kappetein AP, for the SYNTAX investigators (2009).Presented at ESC

22 Long term Follow ups and End Points: Recent meta analyses comparing PCI [BMS/DES] with bypass surgery No diverge of hard events throughout 3 years. Follow-up to 8 years, there was no significant difference in death or MI between PCI (BMS) and CABG. With respect to DES, 5-year follow-up of the ARTS II trial, did not demonstrate a difference in hard end points between DES and CABG. Daemen J et al. Circulation.2008; 118: Hannan EL et al. N Engl J Med :

23 Sub Groups Analysis SYNTAX is a major, landmark study that aims to provide evidence-based, contemporary, objective randomized data about revascularization of 3VD and LM patients Serruys PW, Morice MC et al. N Engl J Med.2009; 360:

24 Absolute difference in 12 months clinical event rate in the SYNTAX trial: Left main Disease Patients with left main disease and low or intermediate Syntax score had benefit from PCI. Serruys PW, Mohr FW. presented at TCT 2008

25 Left main disease: Syntax Trial Breakthrough in interventional therapy of unprotected left main disease. For the first time, clinical efficacy was proven in a large randomized controlled trial: 1/3 of included patients with left main disease No difference in MACCE after 12 months between PCI and CABG Low and intermediate Syntax score may be have better outcome by PCI. Serruys PW, Morice MC et al. N Engl J Med.2009; 360:

26 Absolute difference in 12 months clinical event rate in the SYNTAX trial: Three vessel disease population Low SYNTAX score in three vessel disease can switch the pendulum back towards PCI

27 Absolute difference in 12 months clinical event rate in the SYNTAX trial: Diabetes Mellitus

28 Three-vessel disease and diabetes Death, MI and stroke higher for diabetic patients, but true for PCI and CABG. Reduction of MACCE with CABG compared to PCI was more pronounced than in the overall study population. So presence of diabetis must be weighted in favor of bypass surgery, when making a decision about revascularization strategy except for low Syntax score. Banning AP et al. J Am Coll Cardiol,2010

29 Subgroups and Heart Team decision making Revascularization strategy cannot be based on belonging to a single subgroup characteristics. Discussion between surgeons and cardiologists to integrate all these factors into one decision, which best matches the need of the patient. Patient s age and comorbidity have to be considered, whereby a high surgical risk (e.g. high EuroSCORE) choosing an interventional revascularization procedure. Mohr FW, Serruys PW, for the SYNTAX investigators (2009) Presented at ESC 2009.

30 Technical considerations Development of procedural techniques and devices until the trial is finished may have outdated the ones initially used. This may especially apply for PCI, with new stent generations every couple of years, the new generation having proven superiority versus the Taxus stent( less Stent thrombosis, less events).

31 Completeness of revascularization Investigators in SYNTAX too aggressive in PCI, full metal jacket, period of the» DES euphoria» Average stents per patient = 4.6 ± 2.3 with 48% receiving > 5 stents. FAME study - only hemodynamically relevant stenosis should be treated by PCI,by measuring FFR. Number of stenosis to be stented could be reduced by 37% accompanied by a significant reduction in MACE rates. Hong MK et al. Eur Heart J.2006; 27: Tonino PA et al. N Engl J Med.2009; 360:

32 SYNTAX trial: The Reality Difference is driven by the weakest end point - repeated revascularisation. Combined hard events did not demonstrate a difference. Left main disease is no longer a domain of CABG, since DES implantation revealed comparable results.

33 REBUTTAL

34 Scenario before SYNTAX Cardiac Surgeon - Guidelines favor CABG surgery in three-vessel disease. Left Main is the exclusive domain of surgeons Cardiologist - data favoring surgery based on antique studies comparing CABG surgery with PTCA Until now, no statistical difference in hard endpoints that really matter was seen - death and myocardial infarction. PCI is limited by restenosis, surgery is associated with a higher percentage in stroke.

35 Scenario after SYNTAX Interventional Cardiologist: Thinks & Tells SYNTAX questionable primary endpoint definition only driven by TVR. impact of hospital stay, surgical complications, and cognitive decline were excluded PCI or surgery both are options with advantages and problems. With PCI, you may need another stent, but only 1 2 additional days in hospital. With surgery, a good long-term solution but will have a higher risk of stroke and the inconveniencies of major surgery.

36 Scenario after SYNTAX Cardiac Surgeon: Thinks Cardiac surgeon argues that there is still no justified choice between surgery and PCI SYNTAX demonstrates that CABG remains the gold standart for 3V and LM patients End of story? NO!

37 Cardiologists and Surgeons had learned from each others thanks to Syntax Trial Surgery is the first choice for patients with severe threevessel disease and medium or high SYNTAX score. PCI represents a good alternative for patients with three vessel disease and/or left main stenosis in cases where coronary anatomy is suitable for PCI with a reasonable number of stents. Patient has to be understood in all his aspects, not only in the number of coronary stenoses, but also in his wishes, fears, cultural habits and local economy.

38 TAXUS Stent MACCE (%) MACCE per centers CABG vs. TAXUS TAXUS Stent MACCE (%)100 Institut Jacques Cartier (France) CABG MACCE (%)

39 Main clinical implication of SYNTAX SYNTAX was a true landmark study, certainely the best negative trial of the decade The study design can be regarded as a model for daily clinical practice. A meticulous analysis of coronary pathology by surgeon and cardiologist. A careful individual risk assessment and a consensus decision of all, who were involved A Team Approach.

40 Thank you for your attention

Surgery Grand Rounds

Surgery Grand Rounds Surgery Grand Rounds Coronary Artery Bypass Grafting versus Coronary Artery Stenting Charles Ted Lord, R1 Coronary Artery Disease Stenosis of epicardial vessels Metabolic & hematologic Statistics 500,000

More information

PCI vs. CABG From BARI to Syntax, Is The Game Over?

PCI vs. CABG From BARI to Syntax, Is The Game Over? PCI vs. CABG From BARI to Syntax, Is The Game Over? Seung-Jung Park, MD, PhD Professor of Medicine, University of Ulsan College of Medicine Asan Medical Center, Seoul, Korea PCI vs CABG Multi-Vessel Disease

More information

Management of cardiovascular disease - coronary interventions -

Management of cardiovascular disease - coronary interventions - Master Classes in Preventive Cardiology I Management of diabetes in patients with CVD European Heart House Management of cardiovascular disease - coronary interventions - Francesco Cosentino MD, PhD, FESC

More information

EXCEL vs. NOBLE: How to Treat Left Main Disease in 2017 AATS International Cardiovascular Symposium December 8-9, 2017

EXCEL vs. NOBLE: How to Treat Left Main Disease in 2017 AATS International Cardiovascular Symposium December 8-9, 2017 EXCEL vs. NOBLE: How to Treat Left Main Disease in 2017 AATS International Cardiovascular Symposium December 8-9, 2017 Igor F. Palacios, MD Director of Interventional Cardiology Professor of Medicine Massachusetts

More information

PCI for Left Main Coronary Artery Stenosis. Jean Fajadet Clinique Pasteur, Toulouse, France

PCI for Left Main Coronary Artery Stenosis. Jean Fajadet Clinique Pasteur, Toulouse, France PCI for Left Main Coronary Artery Stenosis Jean Fajadet Clinique Pasteur, Toulouse, France Athens, October 19, 2018 Left Main Coronary Artery Disease Significant unprotected left main coronary artery disease

More information

Rationale for Percutaneous Revascularization ESC 2011

Rationale for Percutaneous Revascularization ESC 2011 Rationale for Percutaneous Revascularization Marie Claude Morice, Massy FR MD, FESC, FACC ESC 2011 Paris Villepinte - 27-31 August, 2011 Massy, France Potential conflicts of interest I have the following

More information

The SYNTAX-LE MANS Study

The SYNTAX-LE MANS Study The SYNTAX-LE MANS Study Synergy Between PCI with TAXUS Express and Cardiac Surgery: Late (15-month) Left Main Angiographic Substudy A. Pieter Kappetein, MD, PhD Erasmus MC, Rotterdam, NL SYNTAX-LE MANS

More information

Komplexe Koronarintervention heute: Von Syntax zu bioresorbierbaren Stents

Komplexe Koronarintervention heute: Von Syntax zu bioresorbierbaren Stents Komplexe Koronarintervention heute: Von Syntax zu bioresorbierbaren Stents Prof. Dr. med. Julinda Mehilli Medizinische Klinik und Poliklinik I Klinikum der Universität München Campus Großhadern Key Factors

More information

Left Main PCI vs. CABG: Real World

Left Main PCI vs. CABG: Real World Management of Patients with Stable CAD Left Main PCI vs. CABG: Real World Marco Roffi, MD, FESC University Hospital Geneva, Switzerland SYNTAX-LMT The SYNTAX trial included a pre-specified subgroup of

More information

Implications of the New ESC/EACTS Guidelines for Myocardial Revascularization in 2011

Implications of the New ESC/EACTS Guidelines for Myocardial Revascularization in 2011 Implications of the New ESC/EACTS Guidelines for Myocardial Revascularization in 2011 Prof. Dr. Volkmar Falk Klinik für Herz- und Gefäßchirurgie, Universitätsspital Zürich, Schweiz In 2004 headlines were

More information

Δημήτριος Αγγοσράς, FETCS

Δημήτριος Αγγοσράς, FETCS ΣΕΜΙΝΑΡΙΟ ΟΜΑΔΩΝ ΕΡΓΑΣΙΑΣ Δημήτριος Αγγοσράς, FETCS Επίκοσρος Καθηγηηής Καρδιοτειροσργικής Ιαηρική Πανεπιζηημίοσ Αθηνών Πανεπιζηημιακό Γενικό Νοζοκομείο Αηηικόν Randomized Controlled Trials (RCTs) Why

More information

What do the guidelines say?

What do the guidelines say? Percutaneous coronary intervention in 3-vessel disease and main stem What do the guidelines say? Nothing to disclose Dariusz Dudek Institute of Cardiology, Jagiellonian University Krakow, Poland The European

More information

FFR in Multivessel Disease

FFR in Multivessel Disease FFR in Multivessel Disease April, 26 2013 Coronary Physiology in the Catheterization Laboratory Location: European Heart House, Nice, France Pim A.L. Tonino, MD, PhD Hartcentrum, Eindhoven, the Netherlands

More information

Multivessel Coronary Artery Disease : CABG. Zürich, F. Siclari MD

Multivessel Coronary Artery Disease : CABG. Zürich, F. Siclari MD Multivessel Coronary Artery Disease : CABG Zürich, 10.06.2015 F. Siclari MD Coronary Artery Ruptured Plaque Pathological process with definite subsequent vascular changes most of them irreversible CABG

More information

Culprit PCI vs MultiVessel PCI for Acute Myocardial Infarction

Culprit PCI vs MultiVessel PCI for Acute Myocardial Infarction Culprit PCI vs MultiVessel PCI for Acute Myocardial Infarction Dipti Itchhaporia, MD, FACC, FESC Trustee, American College of Cardiology Director of Disease Management, Hoag Hospital Robert and Georgia

More information

Mise à Jour sur le traitement du Pluritronculaire Philippe Généreux, MD

Mise à Jour sur le traitement du Pluritronculaire Philippe Généreux, MD Mise à Jour sur le traitement du Pluritronculaire Philippe Généreux, MD Columbia University Medical Center and The Cardiovascular Research Foundation, New York, USA Hôpital du Sacré-Coeur de Montréal,

More information

FFR and CABG Emanuele Barbato, MD, PhD, FESC Cardiovascular Center Aalst, Belgium

FFR and CABG Emanuele Barbato, MD, PhD, FESC Cardiovascular Center Aalst, Belgium FFR and CABG Emanuele Barbato, MD, PhD, FESC Cardiovascular Center Aalst, Belgium Conflict of Interest Institutional research grants and speaker s fee from St. Jude Medical and Boston Scientic to Cardiovascular

More information

Benefit of Performing PCI Based on FFR

Benefit of Performing PCI Based on FFR Benefit of Performing PCI Based on FFR William F. Fearon, MD Associate Professor Director, Interventional Cardiology Stanford University Medical Center Benefit of FFR-Guided PCI FFR-Guided PCI vs. Angiography-Guided

More information

Coronary Artery Disease: Revascularization (Teacher s Guide)

Coronary Artery Disease: Revascularization (Teacher s Guide) Stephanie Chan, M.D. Updated 3/15/13 2008-2013, SCVMC (40 minutes) I. Objectives Coronary Artery Disease: Revascularization (Teacher s Guide) To review the evidence on whether percutaneous coronary intervention

More information

Unprotected Left Main Stenting: Patient Selection and Recent Experience. Alaide Chieffo. S. Raffaele Hospital, Milan, Italy

Unprotected Left Main Stenting: Patient Selection and Recent Experience. Alaide Chieffo. S. Raffaele Hospital, Milan, Italy Unprotected Left Main Stenting: Patient Selection and Recent Experience Alaide Chieffo S. Raffaele Hospital, Milan, Italy Class IIa (Level B) AHA/ACC 2005 Guidelines Left Main CAD The use of PCI for pts

More information

The Synergy between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery: The SYNTAX Study

The Synergy between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery: The SYNTAX Study The Synergy between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery: The SYNTAX Study Five-Year Results in the French Subset René Koning, MD On behalf of the SYNTAX investigators Three-year

More information

COMMENT DEFINIR UN PLURITRONCULAIRE. Didier Carrié CHU Toulouse Rangueil

COMMENT DEFINIR UN PLURITRONCULAIRE. Didier Carrié CHU Toulouse Rangueil COMMENT DEFINIR UN PLURITRONCULAIRE VISION ANGIOGRAHIQUE DU PLURITRONCULAIRE Didier Carrié CHU Toulouse Rangueil Congrès GRCI 03 Décembre 2010 Pôle Cardiovasculaire et Métabolique Avec quel œil je regarde

More information

Southern Thoracic Surgical Association CABG in 2012: Implications of the New ESC/EACTS Guidelines

Southern Thoracic Surgical Association CABG in 2012: Implications of the New ESC/EACTS Guidelines Southern Thoracic Surgical Association 2011 CABG in 2012: Implications of the New ESC/EACTS Guidelines David P Taggart MD PhD FRCS Professor of Cardiovascular Surgery, University of Oxford Conflicts of

More information

Most Patients with Elective Left Main Disease. Farrel Hellig

Most Patients with Elective Left Main Disease. Farrel Hellig Most Patients with Elective Left Main Disease Should be Treated with PCI! Farrel Hellig Sunnnghill and Sunward Park Hospitals Johannesburg South Africa Everything that can be invented has been invented

More information

When should we indisputably perform CABG? Quand faut-il indiscutablement opérer? Dr Hakim BENAMER

When should we indisputably perform CABG? Quand faut-il indiscutablement opérer? Dr Hakim BENAMER When should we indisputably perform CABG? Quand faut-il indiscutablement opérer? Dr Hakim BENAMER ICPS, Massy ICV-GVM La Roseraie, Aubervilliers Hôpital FOCH, Suresnes Disclosure Statement of Financial

More information

Left Main Intervention: Where are we in 2015?

Left Main Intervention: Where are we in 2015? Left Main Intervention: Where are we in 2015? David A. Cox, MD FSCAI Director, Cardiology Research Associate Director, Cardiac Cath Lab Lehigh Valley Health Network Allentown, PA Fall Fellows Course Laa

More information

VCU Pauley Heart Center: A 2009 US News Top 50 Heart and Heart Surgery Hospital

VCU Pauley Heart Center: A 2009 US News Top 50 Heart and Heart Surgery Hospital VCU Pauley Heart Center: A 2009 US News Top 50 Heart and Heart Surgery Hospital Complex PCI: Multivessel Disease George W. Vetrovec, MD. Kimmerling Chair of Cardiology VCU Pauley Heart Center Virginia

More information

Coronary Revascularization for Patients with Severe Coronary Artery Disease: An Overview of Current Evidence and Treatment Strategies

Coronary Revascularization for Patients with Severe Coronary Artery Disease: An Overview of Current Evidence and Treatment Strategies Review J Jpn Coron Assoc 2015; 21: 267-271 Coronary Revascularization for Patients with Severe Coronary Artery Disease: An Overview of Current Evidence and Treatment Strategies Hiroki Shiomi, Takeshi Kimura

More information

high SYNTAX Score? I Sheiban Division of Cardiology Interventional Card. University of Turin Turin / Italy

high SYNTAX Score? I Sheiban Division of Cardiology Interventional Card. University of Turin Turin / Italy What to do with patients with high SYNTAX Score? I Sheiban Division of Cardiology Interventional Card. University of Turin San Giovanni Battista Hospital Turin / Italy Who are the patients with high SYNTAX

More information

Adecade ago, many cardiac surgeons believed

Adecade ago, many cardiac surgeons believed CABG for Multivessel CAD Recent studies show that CABG is still preferred over PCI for most patients. BY SUBHASIS CHATTERJEE, MD; JOHN C. ALEXANDER, MD; AND PAUL J. PEARSON, MD, PHD Adecade ago, many cardiac

More information

Left Main Intervention: Will it become standard of care?

Left Main Intervention: Will it become standard of care? Left Main Intervention: Will it become standard of care? David Cox, MD FSCAI, FACC Director, Interventional Cardiology Research Associate Director, Cardiac Cath Lab Lehigh Valley Health Network Allentown,

More information

Fractional Flow Reserve: Review of the latest data

Fractional Flow Reserve: Review of the latest data Fractional Flow Reserve: Review of the latest data Michalis Hamilos, MD, PhD, FESC University Hospital of Heraklion Fractional Flow Reserve (FFR) Coronary angiography does not always tell the truth Most

More information

Diabetic Patients: Current Evidence of Revascularization

Diabetic Patients: Current Evidence of Revascularization Diabetic Patients: Current Evidence of Revascularization Alexandra J. Lansky, MD Yale University School of Medicine University College of London The Problem with Diabetic Patients Endothelial dysfunction

More information

FFR Incorporating & Expanding it s use in Clinical Practice

FFR Incorporating & Expanding it s use in Clinical Practice FFR Incorporating & Expanding it s use in Clinical Practice Suleiman Kharabsheh, MD Consultant Invasive Cardiology Assistant professor, Alfaisal Univ. KFHI - KFSHRC Concept of FFR Maximum flow down a vessel

More information

Surgical vs. Percutaneous Revascularization in Patients with Diabetes and Acute Coronary Syndrome

Surgical vs. Percutaneous Revascularization in Patients with Diabetes and Acute Coronary Syndrome Surgical vs. Percutaneous Revascularization in Patients with Diabetes and Acute Coronary Syndrome Chris C. Cook, MD Associate Professor of Surgery Director, CT Residency Program, WVU ACOI 10/17/18 No Disclosures

More information

Michael Mack, M.D. Baylor Healthcare System Heart Hospital Baylor Plano Dallas, TX

Michael Mack, M.D. Baylor Healthcare System Heart Hospital Baylor Plano Dallas, TX Michael Mack, M.D. Baylor Healthcare System Heart Hospital Baylor Plano Dallas, TX Boston Scientific, Inc.- Syntax Trial Steering Committee Member- travel expenses paid by trial sponsor Maquet, Inc.- unpaid

More information

Σεμινάριο Ομάδων Εργασίας Fractional Flow Reserve (FFR) Σε ποιούς ασθενείς; ΔΗΜΗΤΡΗΣ ΑΥΖΩΤΗΣ Επιστ. υπεύθυνος Αιμοδυναμικού Τμήματος, Βιοκλινική

Σεμινάριο Ομάδων Εργασίας Fractional Flow Reserve (FFR) Σε ποιούς ασθενείς; ΔΗΜΗΤΡΗΣ ΑΥΖΩΤΗΣ Επιστ. υπεύθυνος Αιμοδυναμικού Τμήματος, Βιοκλινική ΕΛΛΗΝΙΚΗΚΑΡΔΙΟΛΟΓΙΚΗΕΤΑΙΡΕΙΑ Σεμινάριο Ομάδων Εργασίας 2011 Fractional Flow Reserve (FFR) Σε ποιούς ασθενείς; ΔΗΜΗΤΡΗΣ ΑΥΖΩΤΗΣ Επιστ. υπεύθυνος Αιμοδυναμικού Τμήματος, Βιοκλινική GUIDELINES ON MYOCARDIAL

More information

Left Main Disease: what is left to surgery? Prof. Jacques Monségu CardioVascular Institute Grenoble, France

Left Main Disease: what is left to surgery? Prof. Jacques Monségu CardioVascular Institute Grenoble, France Left Main Disease: what is left to surgery? Prof. Jacques Monségu CardioVascular Institute Grenoble, France Background on LM stenosis 5% of patients undergoing angiography Of the myocardium 80% Bifurcation

More information

Case Report Left Main Stenosis. Percutaneous Coronary Intervention (PCI) or Coronary Artery Bypass Graft Surgery (CABG)?

Case Report Left Main Stenosis. Percutaneous Coronary Intervention (PCI) or Coronary Artery Bypass Graft Surgery (CABG)? Cronicon OPEN ACCESS CARDIOLOGY Case Report Left Main Stenosis. Percutaneous Coronary Intervention (PCI) or Coronary Artery Bypass Graft Surgery (CABG)? Valentin Hristov* Department of Cardiology, Specialized

More information

Abbott Vascular. PROTOCOL EXCEL Clinical Trial

Abbott Vascular. PROTOCOL EXCEL Clinical Trial Abbott Vascular PROTOCOL Clinical Trial Evaluation of XIENCE PRIME or XIENCE V versus Coronary Artery Bypass Surgery for Effectiveness of Left Main Revascularization PCI (1 st gen DES) vs. CABG for Left

More information

Assessing Myocardium at Risk: Applying SYNTAX

Assessing Myocardium at Risk: Applying SYNTAX Assessing Myocardium at Risk: Applying SYNTAX Farouc Jaffer MD PhD FSCAI FACC FAHA Associate Professor of Medicine, Harvard Medical School Director, CAD Program and Chronic Total Occlusion PCI Program

More information

PCI for LMCA lesions A Review of latest guidelines and relevant evidence

PCI for LMCA lesions A Review of latest guidelines and relevant evidence HCS Working Group Seminars Met Hotel, Thursday 14 th February 2013 PCI for LMCA lesions A Review of latest guidelines and relevant evidence Vassilis Spanos Interventional Cardiologist, As. Director 3 rd

More information

Unprotected LM intervention

Unprotected LM intervention Unprotected LM intervention Guideline for COMBAT Seung-Jung Park, MD, PhD Professor of Internal Medicine, Seoul, Korea Current Recommendation for unprotected LMCA Stenosis Class IIb C in ESC guideline

More information

Medical Rx vs PCI vs CABG

Medical Rx vs PCI vs CABG Medical Rx vs PCI vs CABG S. Hinan Ahmed, MD Associate Professor: Cardiology and Cardiothoracic Surgery Program Director: Interventional Fellowship Program Assoc Editor: Cath and Cardiovasc Intervention

More information

PCI in Left Main Disease: Are We There Yet?

PCI in Left Main Disease: Are We There Yet? PCI in Left Main Disease: Are We There Yet? Moderator Mark A. Turco, MD Director Center for Cardiac & Vascular Research Washington Adventist Hospital Takoma Park, Maryland Panelists David E. Kandzari,

More information

The synergy between percutaneous coronary intervention with TAXUS and cardiac surgery study: A surgical perspective

The synergy between percutaneous coronary intervention with TAXUS and cardiac surgery study: A surgical perspective SYNTAX STUDY The synergy between percutaneous coronary intervention with TAXUS and cardiac surgery study: A surgical perspective Jacques van Wyk ABSTRACT Panorama Medi-Clinic and Department of Cardiothoracic

More information

Advances in Cardiovascular Diagnosis and Therapy. No disclosure or conflicts. Outline

Advances in Cardiovascular Diagnosis and Therapy. No disclosure or conflicts. Outline Advances in Cardiovascular Diagnosis and Therapy Firas Zahr, MD Assistant Professor of Medicine Interventional Cardiology University Of Iowa No disclosure or conflicts Outline What is new with revascularization?

More information

Declaration of conflict of interest NONE

Declaration of conflict of interest NONE Declaration of conflict of interest NONE Claudio Muneretto MD, PhD Director of Division of Cardiac Surgery University of Brescia Medical School Italy Hybrid Chymera Different features and potential advantages

More information

FAME STUDY: 2-year Follow-Up & CLINICAL SUBGROUP ANALYSIS

FAME STUDY: 2-year Follow-Up & CLINICAL SUBGROUP ANALYSIS Coronary Physiology In The Cathlab FAME STUDY: 2-year Follow-Up & CLINICAL SUBGROUP ANALYSIS Educational Training Program ESC European Heart House april 7th 9th 2011 Nico H.J.Pijls, MD, PhD Catharina Hospital,

More information

ΑΓΓΕΙΟΠΛΑΣΤΙΚΗ ΣΤΟ ΔΙΑΒΗΤΙΚΟ ΑΣΘΕΝΗ

ΑΓΓΕΙΟΠΛΑΣΤΙΚΗ ΣΤΟ ΔΙΑΒΗΤΙΚΟ ΑΣΘΕΝΗ ΑΓΓΕΙΟΠΛΑΣΤΙΚΗ ΣΤΟ ΔΙΑΒΗΤΙΚΟ ΑΣΘΕΝΗ Νίκος Μεζίλης MD, FESC Κλινική Άγιος Λουκάς Why diabetes is associated with restenosis endothelial dysfunction metabolic alterations accelerated platelet deposition

More information

Cite this article as:

Cite this article as: doi: 10.21037/acs.2018. 05.12 Cite this article as: Ngu JM, Sun LY, Ruel M. Pivotal contemporary trials of percutaneous coronary intervention vs. coronary artery bypass grafting: a surgical perspective..

More information

R&M Solutions

R&M Solutions PCI with DES versus CABG & syntax score Dr. Mohamed Sobhy, MD, FACC, FESC Professor of Cardiology, Alexandria University, Egypt Head of Cardiology Department President of Egyptian Society of Cardiology

More information

DESs in Multivessel Disease

DESs in Multivessel Disease DESs in Multivessel Disease Lessons learned from large registry experience. BY DANIEL W. CARLSON, MD, AND MARK A. TURCO, MD, FACC, FSCAI For patients with limitation of ordinary physical activity secondary

More information

LM stenting - Cypher

LM stenting - Cypher LM stenting - Cypher Left main stenting with BMS Since 1995 Issues in BMS era AMC Restenosis and TLR (%) 3 27 TLR P=.282 Restenosis P=.71 28 2 1 15 12 Ostium 5 4 Shaft Bifurcation Left main stenting with

More information

Important LM bifurcation studies update

Important LM bifurcation studies update 8 th European Bifurcation Club 12-13 October 2012 - Barcelona Important LM bifurcation studies update I Sheiban E-mail: isheiban@yahoo.com Unprotected LM Percutaneous Revascularization What is important

More information

Summary HTA. Drug-eluting stents vs. coronary artery bypass-grafting. HTA-Report Summary. Gorenoi V, Dintsios CM, Schönermark MP, Hagen A

Summary HTA. Drug-eluting stents vs. coronary artery bypass-grafting. HTA-Report Summary. Gorenoi V, Dintsios CM, Schönermark MP, Hagen A Summary HTA HTA-Report Summary Drug-eluting stents vs. coronary artery bypass-grafting in coronary heart disease Gorenoi V, Dintsios CM, Schönermark MP, Hagen A Scientific background The coronary heart

More information

Fractional Flow Reserve: Basics, FAME 1, FAME 2. William F. Fearon, MD Associate Professor Stanford University Medical Center

Fractional Flow Reserve: Basics, FAME 1, FAME 2. William F. Fearon, MD Associate Professor Stanford University Medical Center Fractional Flow Reserve: Basics, FAME 1, FAME 2 William F. Fearon, MD Associate Professor Stanford University Medical Center Conflict of Interest Advisory Board for HeartFlow Research grant from St. Jude

More information

Michael Mack, M.D. Baylor Healthcare System Heart Hospital Baylor Plano Dallas, TX

Michael Mack, M.D. Baylor Healthcare System Heart Hospital Baylor Plano Dallas, TX Michael Mack, M.D. Baylor Healthcare System Heart Hospital Baylor Plano Dallas, TX Maquet, Inc.,- unpaid consultant Cordis, Inc.,- unpaid consultant Boston Scientific, Inc.,- travel expenses paid for Syntax

More information

Resolute in Bifurcation Lesions: Data from the RESOLUTE Clinical Program

Resolute in Bifurcation Lesions: Data from the RESOLUTE Clinical Program Resolute in Bifurcation Lesions: Data from the RESOLUTE Clinical Program Prof. Ran Kornowski, MD, FESC, FACC Director - Division of Interventional Cardiology Rabin Medical Center and Tel Aviv University,

More information

Management of Multivessel CAD: Stenting or CABG?

Management of Multivessel CAD: Stenting or CABG? Management of Multivessel CAD: Stenting or CABG? Filippos Triposkiadis, MD, FESC, FACC Department of Cardiology, University of Thessaly Long-term Outcome of Patients With 3VD Undergoing CABG A Report from

More information

FFR-Guided PCI. 4 th Imaging and Physiology Summit October 29 th, 2010 Seoul, Korea. Stanford

FFR-Guided PCI. 4 th Imaging and Physiology Summit October 29 th, 2010 Seoul, Korea. Stanford 4 th Imaging and Physiology Summit October 29 th, 2010 Seoul, Korea FFR-Guided PCI William F. Fearon, M.D. Associate Professor Division of Cardiovascular Medicine University Medical Center Disclosure Statement

More information

Coronary interventions

Coronary interventions Controversial issues in the management of ischemic heart failure Coronary interventions Maciej Lesiak Department of Cardiology, University Hospital in Poznan none DECLARATION OF CONFLICT OF INTEREST CHF

More information

DES in Diabetic Patients

DES in Diabetic Patients DES in Diabetic Patients Charles Chan, M.D., FACC Gleneagles Hospital Singapore TCT ASIA PACIFIC 2007 Why do diabetics have worse outcome after PCI? More extensive atherosclerosis and diffuse disease Increase

More information

LEFT MAIN PERCUTANEOUS CORONARY INTERVENTION. A/Prof Koh Tian Hai Medical Director National Heart Centre, Singapore

LEFT MAIN PERCUTANEOUS CORONARY INTERVENTION. A/Prof Koh Tian Hai Medical Director National Heart Centre, Singapore LEFT MAIN PERCUTANEOUS CORONARY INTERVENTION A/Prof Koh Tian Hai Medical Director National Heart Centre, Singapore Disclosures Advisory Panel, Asian Medical Board Medtronics, Abbott Vascular. Speaker-honoraria,

More information

Revascularization after Drug-Eluting Stent Implantation or Coronary Artery Bypass Surgery for Multivessel Coronary Disease

Revascularization after Drug-Eluting Stent Implantation or Coronary Artery Bypass Surgery for Multivessel Coronary Disease Impact of Angiographic Complete Revascularization after Drug-Eluting Stent Implantation or Coronary Artery Bypass Surgery for Multivessel Coronary Disease Young-Hak Kim, Duk-Woo Park, Jong-Young Lee, Won-Jang

More information

PCIs on Intermediate Lesions NCDR Cath-PCI Registry

PCIs on Intermediate Lesions NCDR Cath-PCI Registry Practical Application Of Coronary Physiology in The Cath Lab Talal T Attar, MD, MBA, FACC PCIs on Intermediate Lesions NCDR Cath-PCI Registry Fraction of stenoses 50-70% treated with PCI without further

More information

CLINICAL CONSEQUENCES OF THE

CLINICAL CONSEQUENCES OF THE CLINICAL CONSEQUENCES OF THE FAME STUDY TCT ASIA Seoul, Korea, april 26 th, 2012 Nico H. J. Pijls, MD, PhD Catharina Hospital, Eindhoven, The Netherlands GUIDELINES ESC SEPTEMBER 2010 FFR UPGRADED TO LEVEL

More information

The Case for PCI as the Preferred Therapy in Most Patients with Chronic Stable Angina

The Case for PCI as the Preferred Therapy in Most Patients with Chronic Stable Angina The Case for PCI as the Preferred Therapy in Most Patients with Chronic Stable Angina Ajay J. Kirtane,, MD Columbia University Medical Center The Cardiovascular Research Foundation Conflict of Interest

More information

ANGIOPLASY SUMMIT 2007 TCT ASIA PACIFIC. Seoul, Korea: April The problem is exaggerated: Data from Real World Registries

ANGIOPLASY SUMMIT 2007 TCT ASIA PACIFIC. Seoul, Korea: April The problem is exaggerated: Data from Real World Registries ANGIOPLASY SUMMIT 007 TCT ASIA PACIFIC Seoul, Korea: 5-7 7 April 007 15 min Plenary Session: State-of of-the-art Lectures The problem is exaggerated: Data from Real World Registries Antonio Colombo Centro

More information

Unprotected Left Main Coronary Artery Disease in Patients With Low Predictive Risk of Mortality

Unprotected Left Main Coronary Artery Disease in Patients With Low Predictive Risk of Mortality Unprotected Left Main Coronary Artery Disease in Patients With Low Predictive Risk of Mortality Shun Watanabe, MD, Tatsuhiko Komiya, MD, Genichi Sakaguchi, MD, PhD, and Takeshi Shimamoto, MD, PhD Department

More information

Update 2012 Herzchirurgie

Update 2012 Herzchirurgie Update 2012 Herzchirurgie Prof. Dr. Jürg Grünenfelder Klinik für Herz- und Gefässchirurgie UniversitätsSpital Zürich Themenübersicht - update Koronarchirurgie - Syntax 5 Jahre - Freedom 5 Jahre - update

More information

Fractional Flow Reserve and the Results of the FAME Study

Fractional Flow Reserve and the Results of the FAME Study Imaging and Physiology Summit Seoul, Korea November 21 st, 2009 Fractional Flow Reserve and the Results of the FAME Study William F. Fearon, M.D. Assistant Professor Division of Cardiovascular Medicine

More information

Master Class in Preventive Cardiology Focus on Diabetes and Cardiovascular Disease Geneva April

Master Class in Preventive Cardiology Focus on Diabetes and Cardiovascular Disease Geneva April Master Class in Preventive Cardiology Focus on Diabetes and Cardiovascular Disease Geneva April 14 2011 Coronary interventions in patients with diabetes Lars Rydén Karolinska Institutet Stockholm, Sweden

More information

TRATAMIENTO INVASIVO ENFERMEDAD ISQUEMICA ESTABLE. Jonathan Poveda CLINICA BIBLICA 2015

TRATAMIENTO INVASIVO ENFERMEDAD ISQUEMICA ESTABLE. Jonathan Poveda CLINICA BIBLICA 2015 TRATAMIENTO INVASIVO ENFERMEDAD ISQUEMICA ESTABLE Jonathan Poveda CLINICA BIBLICA 2015 COURAGE First coronary angioplasty lesion (circles) two days before (A), immediately after (B), and one month after

More information

Upgrade of Recommendation

Upgrade of Recommendation Challenges in LM PCI Decision-making process for stenting Young-Hak Kim, MD, PhD, Heart Institute, University of Ulsan College of Medicine Asan Medical Center, Seoul, Korea Upgrade of Recommendation for

More information

Can Angiographic Complete Revascularization Improve Outcomes for Patients with Decreased LV Function? NO!

Can Angiographic Complete Revascularization Improve Outcomes for Patients with Decreased LV Function? NO! Can Angiographic Complete Revascularization Improve Outcomes for Patients with Decreased LV Function? NO! Young-Hak Kim, MD, PhD Heart Institute, University of Ulsan College of Medicine Asan Medical Center,

More information

Perspective of LM stenting with Current registry and Randomized Clinical Data

Perspective of LM stenting with Current registry and Randomized Clinical Data Asian Pacific TCT Perspective of LM stenting with Current registry and Randomized Clinical Data Patrick W. Serruys MD PhD Yoshinobu Onuma MD Seung-Jung Park MD, PhD 14:48-15:00, 2009 Symposium Arena, Level

More information

STEMI AND MULTIVESSEL CORONARY DISEASE

STEMI AND MULTIVESSEL CORONARY DISEASE STEMI AND MULTIVESSEL CORONARY DISEASE ΤΣΙΑΦΟΥΤΗΣ Ν. ΙΩΑΝΝΗΣ ΕΠΕΜΒΑΤΙΚΟΣ ΚΑΡΔΙΟΛΟΓΟΣ Α ΚΑΡΔΙΟΛΟΓΙΚΗ ΝΟΣ ΕΡΥΘΡΟΥ ΣΤΑΥΡΟΥ IRA 30-50% of STEMI patients have additional stenoses other than the infarct related

More information

Impact of Chronic Kidney Disease on Long-Term Outcome in Coronary Bypass Candidates Treated with Percutaneous Coronary Intervention

Impact of Chronic Kidney Disease on Long-Term Outcome in Coronary Bypass Candidates Treated with Percutaneous Coronary Intervention Original Article Print ISSN 1738-5520 On-line ISSN 1738-5555 Korean Circulation Journal Impact of Chronic Kidney Disease on Long-Term Outcome in Coronary Bypass Candidates Treated with Percutaneous Coronary

More information

Reconciling the Results of the Randomized Trials

Reconciling the Results of the Randomized Trials Management of Stable Angina in Multivessel Disease: Reconciling the Results of the Randomized Trials Eric A. Cohen MD, FRCPC Schulich Heart Centre Sunnybrook Health Sciences Centre Toronto ON ACC Rockies

More information

How to approach non-infarct related artery disease in patients with STEMI in a limited resource setting

How to approach non-infarct related artery disease in patients with STEMI in a limited resource setting How to approach non-infarct related artery disease in patients with STEMI in a limited resource setting Ahmed A A Suliman, MBBS, FACP, FESC Associate Professor, University of Khartoum Interventional Cardiologist,

More information

Coronary Plaque Sealing: The DEFER Study and more...

Coronary Plaque Sealing: The DEFER Study and more... Coronary Plaque Sealing: The DEFER Study and more... How Waiting Can Be Beneficial in Stable Coronary Artery Disease Patients ESC, Stockholm, 2005 M. Romanens, 21.09.2005 at www.kardiolab.ch DEFER Study:

More information

New Generation Drug- Eluting Stent in Korea

New Generation Drug- Eluting Stent in Korea New Generation Drug- Eluting Stent in Korea Young-Hak Kim, MD, PhD Department of Cardiology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea Purpose To briefly introduce the

More information

HREVS: A Randomized Trial of PCI vs CABG vs Hybrid Revascularization in Patients With Coronary Artery Disease. Vladimir Ganyukov, MD, PhD

HREVS: A Randomized Trial of PCI vs CABG vs Hybrid Revascularization in Patients With Coronary Artery Disease. Vladimir Ganyukov, MD, PhD HREVS: A Randomized Trial of PCI vs CABG vs Hybrid Revascularization in Patients With Coronary Artery Disease Vladimir Ganyukov, MD, PhD Nikita Kochergin MD, Aleksandr Shilov MD, PhD, Roman Tarasov, MD,

More information

Percutaneous coronary intervention in patients with multi-vessel coronary artery disease: a focus on physiology

Percutaneous coronary intervention in patients with multi-vessel coronary artery disease: a focus on physiology REVIEW Korean J Intern Med 2018;33:851-859 Percutaneous coronary intervention in patients with multi-vessel coronary artery disease: a focus on physiology Yun-Kyeong Cho and Chang-Wook Nam Division of

More information

Safety of Single- Versus Multi-vessel Angioplasty for Patients with AMI and Multi-vessel CAD

Safety of Single- Versus Multi-vessel Angioplasty for Patients with AMI and Multi-vessel CAD Safety of Single- Versus Multi-vessel Angioplasty for Patients with AMI and Multi-vessel CAD Mun K. Hong, MD Associate Professor of Medicine Director, Cardiovascular Intervention and Research Weill Cornell

More information

FRACTIONAL FLOW RESERVE: STANDARD OF CARE

FRACTIONAL FLOW RESERVE: STANDARD OF CARE FRACTIONAL FLOW RESERVE: FROM INVESTIGATIONAL TOOL TO STANDARD OF CARE TCT ASIA Seoul, Korea, april 26 th, 2012 Nico H. J. Pijls, MD, PhD Catharina Hospital, Eindhoven, The Netherlands FRACTIONAL FLOW

More information

Quality of Life After Everolimus- Eluting Stents or Bypass Surgery for Treatment of Left Main Coronary Artery Disease:

Quality of Life After Everolimus- Eluting Stents or Bypass Surgery for Treatment of Left Main Coronary Artery Disease: Quality of Life After Everolimus- Eluting Stents or Bypass Surgery for Treatment of Left Main Coronary Artery Disease: Results from the EXCEL Trial Suzanne J. Baron MD MSC on behalf of the EXCEL Investigators

More information

NOBLE and EXCEL: The debate for excellence in dealing with left main stenosis

NOBLE and EXCEL: The debate for excellence in dealing with left main stenosis O P E N A C C E S S 1 Aswan Heart Centre, Aswan, Egypt 2 Sultan Qaboos University Hospital, Muscat, Sultanate of Oman 3 Cairo University, Cairo, Egypt *Email: hatem.hosny@aswanheartcentre.com Lessons from

More information

Long-term outcomes of PCI vs. CABG for ostial/midshaft lesions in unprotected left main coronary artery

Long-term outcomes of PCI vs. CABG for ostial/midshaft lesions in unprotected left main coronary artery Journal of Geriatric Cardiology (2017) 14: 254 260 2017 JGC All rights reserved; www.jgc301.com Research Article Open Access Long-term outcomes of PCI vs. CABG for ostial/midshaft lesions in unprotected

More information

Lésions du tronc commun: Reste t il une place pour la chirugie? Pierre Deharo, CHU TIMONE, Marseille

Lésions du tronc commun: Reste t il une place pour la chirugie? Pierre Deharo, CHU TIMONE, Marseille Lésions du tronc commun: Reste t il une place pour la chirugie? Pierre Deharo, CHU TIMONE, Marseille Disclosure Statement of Financial Interest I currently have, or have had over the last two years, an

More information

Unprotected left main coronary stenting with a second generation drug-eluting stent. One-year clinical follow-up of the LeMaX pilot study.

Unprotected left main coronary stenting with a second generation drug-eluting stent. One-year clinical follow-up of the LeMaX pilot study. Unprotected left main coronary stenting with a second generation drug-eluting stent. One-year clinical follow-up of the LeMaX pilot study. N. Boudou, N. Salvatella, N. Dumonteil, M.C. Morice, O. Darremont,

More information

CABG vs PCI: What do the Guidelines Say?

CABG vs PCI: What do the Guidelines Say? AATS International Cardiovascular Symposium: Sao Paolo 2017 CABG vs PCI: What do the Guidelines Say? David P Taggart MD PhD FRCS FESC Professor of Cardiovascular Surgery, University of Oxford Conflicts

More information

Management of High-Risk Coronary Artery Disease

Management of High-Risk Coronary Artery Disease Management of High-Risk Coronary Artery Disease Jeffrey J. Popma, MD Director, Interventional Cardiology Clinical Services Beth Israel Deaconess Medical Center Associate Professor of Medicine Harvard Medical

More information

SYNTAX III REVOLUTION Trial Press briefing conference. Prof. Patrick W. Serruys MD, PhD Principal Investigator Imperial College of London

SYNTAX III REVOLUTION Trial Press briefing conference. Prof. Patrick W. Serruys MD, PhD Principal Investigator Imperial College of London SYNTAX III REVOLUTION Trial Press briefing conference Prof. Patrick W. Serruys MD, PhD Principal Investigator Imperial College of London Title: Coronary Computed Tomography Angiography for Heart Team Decision-making

More information

Nuevas evidencias en revascularización coronaria: SYNTAX-ASCERT. El debate continúa.

Nuevas evidencias en revascularización coronaria: SYNTAX-ASCERT. El debate continúa. XXXVIII Congreso Argentino de Cardiología TCT@CACI@SAC Nuevas evidencias en revascularización coronaria: SYNTAX-ASCERT. El debate continúa. La visión del cardioangiólogo intervencionista Dr. Alfredo E.

More information

Cindy L. Grines MD FACC FSCAI

Cindy L. Grines MD FACC FSCAI Cindy L. Grines MD FACC FSCAI Hofstra Northwell School of Medicine Chair, Cardiology Academic Chief of Cardiology, Northwell Health North Shore University Hospital, Manhasset NY Multivessel Disease in

More information

Count Down to COMBAT

Count Down to COMBAT Count Down to COMBAT Randomized COMparison of Bypass Surgery versus AngioplasTy using Sirolimus-Eluting Stent in Patients with Left Main Coronary Artery Disease Roxana Mehran, MD Associate Professor of

More information

SAHA PCI or CABG for Left Main and Multi-Vessel Disease: when I would definitely/ maybe/never refer my patient for PCI or CABG

SAHA PCI or CABG for Left Main and Multi-Vessel Disease: when I would definitely/ maybe/never refer my patient for PCI or CABG SAHA 2017 PCI or CABG for Left Main and Multi-Vessel Disease: when I would definitely/ maybe/never refer my patient for PCI or CABG David P Taggart MD PhD FRCS FESC Professor of Cardiovascular Surgery,

More information

Clinical Seminar. Which Diabetic Patient is a Candidate for Percutaneous Coronary Intervention - European Perspective

Clinical Seminar. Which Diabetic Patient is a Candidate for Percutaneous Coronary Intervention - European Perspective Clinical Seminar Which Diabetic Patient is a Candidate for Percutaneous Coronary Intervention - European Perspective Stephan Windecker Department of Cardiology Swiss Cardiovascular Center and Clinical

More information